Stifel Financial Corp Acquires 55,288 Shares of Eli Lilly and Company (NYSE:LLY)

Stifel Financial Corp increased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 7.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 799,416 shares of the company's stock after purchasing an additional 55,288 shares during the period. Eli Lilly and Company accounts for 0.6% of Stifel Financial Corp's investment portfolio, making the stock its 24th largest holding. Stifel Financial Corp owned 0.08% of Eli Lilly and Company worth $617,203,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. Optivise Advisory Services LLC raised its position in Eli Lilly and Company by 1.9% during the 4th quarter. Optivise Advisory Services LLC now owns 1,991 shares of the company's stock worth $1,537,000 after buying an additional 37 shares during the last quarter. Senator Investment Group LP increased its stake in shares of Eli Lilly and Company by 286.8% during the fourth quarter. Senator Investment Group LP now owns 85,101 shares of the company's stock worth $65,698,000 after acquiring an additional 63,101 shares during the period. Van Lanschot Kempen Investment Management N.V. lifted its position in Eli Lilly and Company by 33.7% in the fourth quarter. Van Lanschot Kempen Investment Management N.V. now owns 28,804 shares of the company's stock valued at $22,237,000 after purchasing an additional 7,255 shares during the period. Wealth Dimensions Group Ltd. increased its position in Eli Lilly and Company by 8.0% during the 4th quarter. Wealth Dimensions Group Ltd. now owns 3,518 shares of the company's stock worth $2,716,000 after purchasing an additional 260 shares during the period. Finally, Teachers Retirement System of The State of Kentucky raised its stake in shares of Eli Lilly and Company by 8.7% during the 4th quarter. Teachers Retirement System of The State of Kentucky now owns 107,040 shares of the company's stock worth $82,635,000 after buying an additional 8,528 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.13% of the company's stock.

Analyst Ratings Changes

LLY has been the subject of a number of recent analyst reports. Berenberg Bank set a $970.00 target price on Eli Lilly and Company in a report on Thursday, January 16th. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their price objective for the company from $892.00 to $888.00 in a research note on Tuesday, April 8th. StockNews.com upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Friday, February 7th. Citigroup cut their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a report on Tuesday, January 28th. Finally, Cantor Fitzgerald began coverage on Eli Lilly and Company in a report on Tuesday. They issued an "overweight" rating and a $975.00 price target for the company. Two research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of "Moderate Buy" and an average price target of $1,017.00.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY traded up $3.03 during mid-day trading on Wednesday, hitting $830.57. The company had a trading volume of 2,712,888 shares, compared to its average volume of 3,432,615. The stock has a market cap of $787.52 billion, a price-to-earnings ratio of 70.93, a PEG ratio of 1.40 and a beta of 0.51. The firm's 50 day simple moving average is $827.10 and its two-hundred day simple moving average is $818.99. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.